Lead Sponsor

Novartis Pharmaceuticals

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Adult patients (≥18 years old) with advanced hematological malignancies who relapsed after or are refractory to standard therapy, or for which no standard therapy existed; or, were considered inappropriate candidates for standard therapy
•World Health Organization (WHO) performance status ≤ 2
•Patients who met protocol-specified hematologic and non-hematologic laboratory values
•Patients with adequate liver and renal function

•Concurrent brain metastases or leukemic infiltration of the cerebrospinal fluid
•Peripheral neuropathy ≥ CTCAE grade 2
•Unresolved diarrhea ≥ CTCAE grade 2
•Concurrent severe and/or uncontrolled medical conditions which could compromise participation in the study, including impaired heart function or clinically significant heart disease, and impaired gastrointestinal function or disease that significantly altered aborption of LBH589
•Female patients who were pregnant or breast feeding
•Patients who were unwilling to use an effective method of birth control
•Patients who took medications specified by the protocol as prohibited for administration in combination with LBH589
•Patients with another primary malignancy that required active intervention or were clinically significant

Related studies

NCT06191978 · Acute Myeloid Leukemia

NCT06395103 · B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, and more

NCT06317649 · Acute Myeloid Leukemia

NCT07053436 · High Risk Newly Diagnosed Multiple Myeloma

NCT06615479 · Relapsed or Refractory Multiple Myeloma (RRMM)

A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies